Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

Nanologica

0.37 SEK

+5.43 %

Less than 1K followers

NICA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.43 %
+0.60 %
-52.28 %
-47.28 %
-68.85 %
-75.99 %
-95.73 %
-97.71 %
-97.95 %

Nanologica is a life science tools company that develops, manufactures and sells advanced input products to pharmaceutical companies. Nanologica's silica-based products are specifically designed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Nanologica operates in a global niche market for drugs for the treatment of diabetes and obesity. Nanologica was founded in 2004 and is headquartered in Södertälje.

Read more
Market cap
121.32M SEK
Turnover
93.65K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/5
2026

Interim report Q1'26

28/5
2026

General meeting '26

27/8
2026

Interim report Q2'26

All
Press releases
3rd party
ShowingAll content types
Regulatory press release5 hours ago

Nanologica offentliggör utfall i företrädesemission

Nanologica
Regulatory press release5 hours ago

Nanologica Announces Outcome of Rights Issue

Nanologica
Regulatory press release3/19/2026, 9:17 AM

Finansinspektionen: Flaggningsmeddelande i Nanologica AB (publ)

Nanologica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/10/2026, 8:48 AM

Valberedningen föreslår nyval av Mark Quick och Erik Haeffler som styrelseledamöter i Nanologica AB (publ)

Nanologica
Regulatory press release3/10/2026, 8:48 AM

The Nomination Committee Proposes Election of Mark Quick and Erik Haeffler as New Board Members of Nanologica AB (publ)

Nanologica
Regulatory press release3/10/2026, 6:48 AM

Nanologica offentliggör utfallet i riktade nyemissioner

Nanologica
Regulatory press release3/10/2026, 6:48 AM

Nanologica Announces Outcome of Directed Share Issues

Nanologica
Regulatory press release3/6/2026, 7:28 AM

Nanologica offentliggör informationsdokument avseende riktade nyemissioner och företrädesemission

Nanologica
Regulatory press release3/6/2026, 7:28 AM

Nanologica Publishes Information Document Regarding Directed Share Issues and Rights Issue

Nanologica
Regulatory press release3/4/2026, 9:56 AM

KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

Nanologica
Regulatory press release3/4/2026, 9:56 AM

BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

Nanologica
Regulatory press release2/26/2026, 7:10 AM

Bokslutskommuniké 2025 Nanologica AB (publ)

Nanologica
Regulatory press release2/26/2026, 7:10 AM

Year-End Report 2025 Nanologica AB (publ)

Nanologica
Press release2/10/2026, 8:52 AM

Jeremie Trochu föreslås som ny styrelseledamot i Nanologica AB (publ)

Nanologica
Press release2/10/2026, 8:52 AM

Jeremie Trochu Proposed as New Board Member of Nanologica AB (publ)

Nanologica
Regulatory press release1/30/2026, 7:22 AM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

Nanologica
Regulatory press release1/30/2026, 7:22 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

Nanologica
Regulatory press release1/30/2026, 7:16 AM

NANOLOGICA GENOMFÖR RIKTADE EMISSIONER OM TOTALT CIRKA 13,7 MSEK SAMT EN FULLT SÄKERSTÄLLD FÖRETRÄDESEMISSION OM CIRKA 82,5 MSEK

Nanologica
Regulatory press release1/30/2026, 7:16 AM

NANOLOGICA CARRIES OUT DIRECTED SHARE ISSUES OF APPROX. SEK 13.7 MILLION IN TOTAL, AND A FULLY SECURED RIGHTS ISSUE OF APPROX. SEK 82.5 MILLION

Nanologica
Regulatory press release1/29/2026, 5:07 PM

Nanologica AB (publ) förvärvar Ardena Södertälje AB

Nanologica
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.